MedPath

A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: RO5285119
Registration Number
NCT02179866
Lead Sponsor
Hoffmann-La Roche
Brief Summary

This study is designed to investigate the absorption, distribution, metabolism and elimination of a single oral dose of radiolabeled \[14C\]-labeled RO5285119 in healthy male participants.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
6
Inclusion Criteria
  • Healthy male participants, 35 to 64 years of age, inclusive
  • For men with a female partner of child-bearing potential: Agreement to use two methods of contraception, including one barrier method e.g. condom, during the treatment period and for at least 3 months after the last dose of study drug
  • Participants who do not intend to donate sperm until at least 3 months after the last dose of the study drug
Read More
Exclusion Criteria
  • History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer or cirrhosis
  • Any personal or familial history of seizures, epilepsy or other convulsive condition, previous significant head trauma, or other factors predisposing to seizures
  • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to a subject
  • History or presence of any clinically relevant ECG abnormalities, cardiovascular or cerebrovascular disease
  • History of myopathy or muscle disorder
  • History or evidence of any medical condition potentially altering the absorption, metabolism or elimination of drugs
  • Any CYP3A inhibitor within 2 weeks or within 5 times the elimination half-life, whichever is longer, prior to dosing
  • Any CYP3A inducer within 4 weeks or within 5 times the elimination half-life, whichever is longer, prior to dosing
  • Infrequent bowel movements (less than once per 24 hours on average)
  • Regular work with ionizing radiation or radioactive material
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
[14C]-labeled RO5285119RO5285119Single oral dose - drinking solution
Primary Outcome Measures
NameTimeMethod
Total recovery of radioactivity over time in urine and feces expressed as a percentage of the total radioactive dose administeredUp to Day 17
Pharmacokinetic profile of total drug-related material, RO5285119 and its metabolites, as appropriate in plasma, estimated CmaxUp to Day 17
Secondary Outcome Measures
NameTimeMethod
Percent of dose recovered as total radioactivity, i.e. relative abundance of RO5285119 and its metabolite(s) in plasma, urine and fecesUp to Day 17
Incidence of adverse eventsUp to 28 days after the last dose of study drug
© Copyright 2025. All Rights Reserved by MedPath